Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ

16 Jan 2025

Abstract excerpt

Importance: Intratumoral immunotherapy that leverages the biological characteristics of high-risk ductal carcinoma in situ (DCIS) may be able to reduce the extent of surgical treatment and provide an alternative approach to improve patient outcomes. Objective: To determine if combination intratumoral immunotherapy can activate immune cells to shrink or eliminate high-risk DCIS. Design, Setting, and Participants:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Head and Neck Cancer Studies

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39821301
DOI: 10.1001/jamaoncol.2024.5927

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In SituPMID 39821301Read ↗

Tumor microenvironmental determinants of high-risk DCIS progressionSemantic proximity Read ↗

Tumor microenvironmental determinants of high-risk DCIS progressionSemantic proximity Read ↗

Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune SystemSemantic proximity Read ↗

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responsesSemantic proximity Read ↗

Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.Semantic proximity Read ↗

Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactionsSemantic proximity Read ↗

Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trialSemantic proximity Read ↗

Spatially Aware Mammography and Ultrasound Analysis for Preoperative Prediction of Upstaging in Biopsy-Diagnosed Ductal Carcinoma In SituSemantic proximity Read ↗

Association of the 12-gene Breast DCIS Score® assay with local recurrence in patients with ductal carcinoma in situ treated on accelerated partial breast radiotherapy protocolsSemantic proximity Read ↗

Intratumoral administration of mRNA-1273 vaccine delays melanoma growth in miceSemantic proximity Read ↗

Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltrationSemantic proximity Read ↗

Turning anecdotal irradiation-induced anti-cancer immune responses into reproducible in situ cancer vaccines via disulfiram/copper-mediated enhanced immunogenic cell death of breast cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.